Metastatic breast cancer often exhibits elevated levels of Trop-2, a transmembrane calcium signal transducer, which contributes to tumor growth and advancement, providing the rationale for testing anti-Trop2 treatment strategies in these patients. This evidence concerns the gene TACSTD2 and breast cancer.